Herantis Pharma (HRTIS.HE) Stock Analysis & AI Equity Report
Herantis Pharma (HRTIS.HE) overview
Herantis Pharma (HRTIS.HE) stock analysis and AI equity research. For the latest completed financial year, 2025, Herantis Pharma reported revenue of EUR 0m and operating profit of EUR -6.4m; the year-end share price was 2.04 EUR and market capitalisation was EUR 48.2m. Herantis Pharma is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Herantis Pharma's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Herantis Pharma
Herantis Pharma Oyj is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative diseases, particularly Parkinson’s disease. Its lead program, HER-096, is a CDNF-derived peptide being advanced through clinical development. The company aims to build value through product development and strategic partnerships for later-stage clinical testing and commercialization.
Generate the Herantis Pharma report
Herantis Pharma is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Herantis Pharma and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Herantis Pharma
Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.